

1 **Title**

2 Discovery of 318 novel loci for type-2 diabetes and related micro- and macrovascular outcomes among  
3 1.4 million participants in a multi-ethnic meta-analysis.

4

5 **Authors**

6 Marijana Vujkovic\*, Ph.D., MSCE<sup>1,2</sup>, Jacob M. Keaton\*, Ph.D.<sup>3,4,5,6</sup>, Julie A. Lynch, Ph.D., R.N.<sup>7,8</sup>, Donald R.  
7 Miller, Sc.D.<sup>9,10</sup>, Jin Zhou, Ph.D.<sup>11,12</sup>, Catherine Tcheandjieu, Ph.D.<sup>13,14,15</sup>, Jennifer E. Huffman,  
8 Ph.D.<sup>16</sup>, Themistocles L. Assimes, M.D., Ph.D.<sup>13,14</sup>, Renae L. Judy<sup>1,17</sup>, Jie Huang, Ph.D.<sup>16,18</sup>, Kyung Min Lee,  
9 Ph.D.<sup>7</sup>, Derek Klarin, M.D.<sup>16,19,20,21</sup>, Saiju Pyarajan<sup>16,22</sup>, John Danesh, M.D., Ph.D.<sup>23</sup>, Olle Melander, M.D.,  
10 Ph.D.<sup>24</sup>, Asif Rasheed, Ph.D.<sup>25</sup>, Nadeem Qamar, M.D., Ph.D.<sup>26</sup>, Saqib S. Sheikh, M.D., Ph.D.<sup>27</sup>, Shahid  
11 Hameed, M.D., Ph.D.<sup>27</sup>, Irshad H. Qureshi, M.D., Ph.D.<sup>28,29</sup>, Muhammad N. Afzal, M.D.<sup>28,29</sup>, Uzma  
12 Jahazaib, M.D.<sup>28,29</sup>, Anjum Jalal, M.D., Ph.D.<sup>30</sup>, Shahid Abbas, Ph.D.<sup>30</sup>, Xin Sheng, Ph.D.<sup>2</sup>, Long Gao,  
13 Ph.D.<sup>31</sup>, Klaus H. Kaestner, Ph.D.<sup>31</sup>, Katalin Susztak, M.D.<sup>2</sup>, Yan V. Sun, Ph.D.<sup>32,33</sup>, Scott L. Duvall,  
14 Ph.D.<sup>7,34</sup>, Kelly Cho, Ph.D., MPH<sup>16,22</sup>, Jennifer S. Lee, M.D., Ph.D.<sup>13,35</sup>, John M. Gaziano, M.D.<sup>16,22</sup>, Lawrence  
15 S. Philips, M.D.<sup>36,37</sup>, James B. Meigs, M.D.<sup>20,38,39,40</sup>, Peter D. Reaven, M.D.<sup>11,41</sup>, Peter W. Wilson,  
16 M.D.<sup>36,42</sup>, Todd L. Edwards, Ph.D.<sup>4,43</sup>, Daniel J. Rader, M.D.<sup>2</sup>, Scott M. Damrauer, M.D.<sup>1,17</sup>, Christopher J.  
17 O'Donnell, M.D.<sup>16,22</sup>, Philip S. Tsao, Ph.D.<sup>13,35</sup>, HPAP Consortium, Regeneron Genetics Center, VA Million  
18 Veteran Program, Kyong-Mi Chang\*, M.D.<sup>1,2</sup>, Benjamin F. Voight\*, Ph.D.<sup>1,31,44</sup>, Danish Saleheen\*, M.D.,  
19 Ph.D.<sup>25,45,46</sup>

20

21 *\*These authors contributed equally*

22

## 23 Affiliations

24 <sup>1</sup>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA, <sup>2</sup>Department of Medicine,  
25 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, <sup>3</sup>Biomedical Laboratory  
26 Research and Development, Tennessee Valley Healthcare System, Nashville, TN, USA, <sup>4</sup>Vanderbilt  
27 Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA, <sup>5</sup>Department of Medicine,  
28 Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA, <sup>6</sup>Department of  
29 Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA, <sup>7</sup>VA Salt Lake City  
30 Health Care System, Salt Lake City, UT, USA, <sup>8</sup>College of Nursing and Health Sciences, University of  
31 Massachusetts, Boston, MA, USA, <sup>9</sup>Edith Nourse Rogers Memorial VA Hospital, Bedford, MA,  
32 USA, <sup>10</sup>Department of Health Law, Policy and Management, Boston University School of Public Health,  
33 Boston, MA, USA, <sup>11</sup>Phoenix VA Health Care System, Phoenix, AZ, USA, <sup>12</sup>Mel and Enid Zuckerman  
34 College of Public Health, University of Arizona, Tucson, AZ, USA, <sup>13</sup>VA Palo Alto Health Care System, Palo  
35 Alto, CA, USA, <sup>14</sup>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford,  
36 CA, USA, <sup>15</sup>Department of Pediatric Cardiology, Stanford University School of Medicine, Stanford, CA,  
37 USA, <sup>16</sup>VA Boston Healthcare System, Boston, MA, USA, <sup>17</sup>Department of Surgery, University of  
38 Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, <sup>18</sup>Department of Global Health,  
39 Peking University School of Public Health, Beijing, Beijing, China, <sup>19</sup>Center for Genomic Medicine,  
40 Massachusetts General Hospital, Boston, MA, USA, <sup>20</sup>Program in Medical and Population Genetics, Broad  
41 Institute of MIT and Harvard, Cambridge, MA, USA, <sup>21</sup>Division of Vascular Surgery and Endovascular  
42 Therapy, University of Florida School of Medicine, Gainesville, FL, USA, <sup>22</sup>Department of Medicine,  
43 Brigham Women's Hospital, Boston, MA, USA, <sup>23</sup>Department of Public Health and Primary Care,  
44 University of Cambridge, Cambridge, UK, <sup>24</sup>Department of Internal Medicine, Lund University, Lund,  
45 Sweden, <sup>25</sup>Center for Non-Communicable Diseases, Karachi, Sindh, Pakistan, <sup>26</sup>National Institute of  
46 Cardiovascular Diseases, Karachi, Sindh, Pakistan, <sup>27</sup>Punjab Institute of Cardiology, Lahore, Punjab,

47 Pakistan, <sup>28</sup>Department of Medicine, King Edward Medical University, Lahore, Punjab, Pakistan, <sup>29</sup>Mayo  
48 Hospital, Lahore, Punjab, Pakistan, <sup>30</sup>Department of Cardiology, Faisalabad Institute of Cardiology,  
49 Faisalabad, Punjab, Pakistan, <sup>31</sup>Department of Genetics, University of Pennsylvania Perelman School of  
50 Medicine, Philadelphia, PA, USA, <sup>32</sup>Atlanta VA Health Care System, Atlanta, GA, USA, <sup>33</sup>Department of  
51 Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA, <sup>34</sup>Department of  
52 Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA, <sup>35</sup>Department of Medicine,  
53 Stanford University School of Medicine, Stanford, CA, USA, <sup>36</sup>Atlanta VA Medical Center, Atlanta, GA,  
54 USA, <sup>37</sup>Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA, <sup>38</sup>Division of  
55 General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA, <sup>39</sup>Department of  
56 Medicine, Harvard Medical School, Boston, MA, USA, <sup>40</sup>Program in Metabolism, Broad Institute of MIT  
57 and Harvard, Cambridge, MA, USA, <sup>41</sup>College of Medicine, University of Arizona, Tucson, AZ,  
58 USA, <sup>42</sup>Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA, <sup>43</sup>Nashville VA  
59 Medical Center, Nashville, TN, USA, <sup>44</sup>Department of Systems Pharmacology and Translational  
60 Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA,  
61 USA, <sup>45</sup>Department of Medicine, Columbia University Irving Medical Center, New York, NY,  
62 USA, <sup>46</sup>Department of Cardiology, Columbia University Irving Medical Center, New York, NY, USA

63

64 **Main text word count**

65 3.999

66

67 **Subject codes**

68 Type 2 Diabetes, population genetics, genome-wide association studies, diabetic complications

69

70 **Corresponding Authors**

71 Danish Saleheen, M.D., Ph.D.

72 Email: [ds3792@cumc.columbia.edu](mailto:ds3792@cumc.columbia.edu)

73 Office: 10-401 College of Physicians & Surgeons

74 630 West 168th Street, New York, NY 10032

75 Tel: (212) 305-3508

76 Fax: (212) 305-3213

77

78 Benjamin F. Voight, Ph.D.

79 Email: [bvoight@penntranslational.upenn.edu](mailto:bvoight@penntranslational.upenn.edu)

80 Office: 10-126 Smilow Center for Translational Research

81 3400 Civic Center Boulevard, Philadelphia, PA 19104

82 Tel: (215) 746-8083

83 Fax: (215) 573-9135

84

85

86 **We investigated type 2 diabetes (T2D) genetic susceptibility in a multi-ethnic meta-analysis of 228,499**  
87 **cases and 1,178,783 controls in the Million Veteran Program (MVP) and other biobanks. We identified**  
88 **558 autosomal and 10 X-chromosome T2D-associated variants, of which 286 autosomal and 7 X-**  
89 **chromosome variants were previously unreported. Ancestry-specific analyses identified 25 additional**  
90 **novel T2D-susceptibility variants. Transcriptome-wide association analysis detected 3,568 T2D-**  
91 **associations with T2D-colocalized genetically predicted gene expression of 804 genes in 52 tissues, of**  
92 **which 687 are novel. Fifty-four of these genes are known to interact with FDA-approved drugs and**  
93 **chemical compounds. T2D polygenic risk score was strongly associated with increased the risk of T2D-**  
94 **related retinopathy, and additionally showed evidence for association with chronic kidney disease**  
95 **(CKD), neuropathy, and peripheral artery disease (PAD). We investigated the genetic etiology of T2D-**  
96 **related vascular outcomes in the MVP and observed statistical SNP-T2D interactions at 13 variants,**  
97 **including 3 for coronary heart disease, 1 for PAD, 2 for stroke, 4 for retinopathy, 2 for CKD, and 1 for**  
98 **neuropathy. Our findings may identify potential novel therapeutic targets for T2D and genomic**  
99 **pathways that link T2D and its vascular outcomes.**

100

101 Type 2 diabetes mellitus (T2D) - a leading cause of morbidity globally - is projected to affect up to 629  
102 million people by 2045<sup>1</sup>. People with T2D are at increased risk of developing a wide range of macro- and  
103 microvascular outcomes<sup>2</sup>, and there are large disparities in prevalence, severity and co-morbidities  
104 across global populations. T2D is highly polygenic and over 400 common variants have been identified  
105 that confer disease susceptibility; however, most studies have been performed in European and Asian  
106 ancestry populations, and dominant risk alleles in other ethnic groups remain to be discovered. The  
107 genetic etiology of T2D-related sequelae remain poorly understood. Identifying genetic risks and critical  
108 genes for T2D-related micro- and macrovascular disease could inform clinical management strategies,  
109 including patient stratification and optimizing study design of randomized controlled trials for novel  
110 treatments. The lack of large-scale multi-ethnic deeply phenotyped cohorts linked to genetic data has  
111 made it difficult to address these questions.

112 We conducted a multi-ethnic association study of T2D risk comprised of 228,499 T2D cases and  
113 1,178,783 controls of European, African American, Hispanic, South Asian, and East Asian ancestry. We  
114 investigated the association of a T2D polygenic risk score with 3 major T2D-related macrovascular  
115 outcomes (coronary heart disease [CHD], ischemic stroke, and peripheral artery disease [PAD]) and 3  
116 microvascular disease (chronic kidney disease [CKD], retinopathy and neuropathy) in the Million Veteran  
117 Program (MVP)<sup>3</sup>. We conducted a genome-wide SNP-T2D interaction analysis on vascular outcomes in  
118 MVP to identify genetic variants where the effect of SNP on the vascular outcome depends on the  
119 context of T2D presence. We also performed association analyses of genetically-predicted expression  
120 levels and expression quantitative trait-T2D colocalization analyses to identify the effects of gene-tissue  
121 pairs that influence T2D risk through inter-individual variation in expression.

122 This study differs from prior GWAS of T2D risk by leveraging large-scale clinical data in  
123 conjunction with polygenic scores, extensive evaluation of context specificity for genetic effects on T2D  
124 vascular sequelae and describing the regulatory circuits that influence T2D risk. These observations

125 move the study of T2D genetics beyond lists of variants and provide novel biological insights with  
126 translational potential.

## 127 **Results**

### 128 *Study Populations.*

129 We performed a genome-wide, multi-ethnic T2D-association analysis (228,499 cases and 1,178,783  
130 controls) encompassing five ancestral groups (Europeans, African Americans, Hispanics, South Asians  
131 and East Asians) by meta-analyzing genome-wide association study (GWAS) summary statistics derived  
132 from the Million Veteran Program (MVP)<sup>3</sup> and other studies with non-overlapping participants:  
133 DIAMANTE Consortium<sup>4</sup>, Penn Medicine Biobank<sup>5</sup>, Pakistan Genomic Resource<sup>6</sup>, Biobank Japan<sup>7</sup>, Malmö  
134 Diet and Cancer Study<sup>8</sup>, Medstar<sup>9</sup>, and PennCath<sup>9</sup> (Online Methods, Supplementary Table 1 and 3). MVP  
135 participants (n = 273,409) are comprised predominantly of male subjects (91.6%) and were classified as  
136 Europeans (72.1%), African Americans (19.5%), Hispanics (7.5%), and Asians (0.9%)(Supplemental Table  
137 2).

### 138 *Single-variant autosomal analyses.*

139 We identified a total of 558 independent sentinel SNPs (286 novel, 272 previously reported)<sup>4,7,10,11</sup>  
140 associated with T2D (Figure 1, Table 1, Supplemental Tables 4, 5, 6, 10, and 11, Supplemental Figure 1a-  
141 e). Variants were classified as novel if they were at least 500 kb distant from a previously reported  
142 sentinel SNP<sup>4,7,10,11</sup> and/or if they were not in linkage disequilibrium (LD,  $r^2 \leq 0.05$ ) with an established  
143 sentinel SNP<sup>4,7,10,11</sup>. A total of 21 SNPs showed genome-wide significance in Europeans only  
144 (Supplemental Table 6). We found that novel loci had, on average, smaller magnitudes of effect ( $0.032 \pm$   
145  $0.012$  per allele) than previously established SNPs ( $0.054 \pm 0.045$  per allele, derived from data shown in  
146 Supplementary Table 5), presumably resulting from enhanced power to discover weaker effects due to

147 the large sample size and ancestral diversity. Genome-wide chip heritability analysis explained 19% of  
148 T2D risk<sup>4</sup>.

149 In an analysis of African American participants (Table 1), we observed a total of 21 loci  
150 associated with T2D susceptibility at genome-wide significance, 16 of which were in strong LD with  
151 established T2D variants. Three variants were novel and the effect on T2D appeared specific to African-  
152 Americans. The frequency of the T2D risk-increasing allele is notably higher in African reference  
153 populations than European for these SNPs, with the ancestral allele the major allele in African  
154 populations and the derived allele being the major allele in European populations. Single variant analysis  
155 in the Hispanics subset identified 2 SNPs, both of which tagged previously reported T2D loci  
156 (Supplemental Table 10). No novel variants were observed in the subjects of Asian ancestry  
157 (Supplemental Table 11).

#### 158 *Chromosome-X analyses.*

159 A total of 10 association signals for T2D were identified on chromosome X in a multi-ethnic  
160 meta-analysis, of which 7 were novel (Table 2a-b, Supplemental Figure 2a-e). A European-restricted  
161 analysis identified 4 chromosome-X loci associated with T2D risk, all of which were identified in the  
162 multi-ethnic meta-analysis. One novel chromosome-X locus was associated with T2D that is specific to  
163 African Americans. Of interest is one novel, multi-ethnic locus near the androgen receptor gene that was  
164 in strong LD with a previously reported variant (rs4509480) known to be associated with male-pattern  
165 baldness (EUR  $r^2=0.98$ , rs200644307).

#### 166 *Effect heterogeneity between Europeans and African Americans.*

167 For most loci, we found no evidence of significant heterogeneity of effect estimates between Europeans  
168 and African Americans, whereas 44 (7.9%) had significantly different effect estimates (Supplemental  
169 Table 20). Overall, the strength of effect was found to be highest in Europeans, an expected result given



170 the abundance of individuals of that ancestry in our study. However, 4 loci nearby the genes *SLC30A8*,  
171 *PTPRQ*, *GRB10*, and *COLB* showed higher effect sizes for T2D at stronger levels of significance in African  
172 Americans compared with Europeans. Of these loci, associations with loss of function variants in the  
173 *SLC30A8* gene were previously reported in Europeans, African Americans and South Asians<sup>12,13</sup>.

#### 174 *Secondary signal analysis.*

175 We detected a total of 233 conditionally independent SNPs that flank 49 novel and 108 previously  
176 reported lead SNPs in Europeans (Supplementary Table 7 and 9), and identified 9 independent variants  
177 in Europeans and 3 in African Americans flanking 3 novel and 6 previously reported sentinel SNPs. We  
178 observed no novel conditionally independent variants in participants of South Asian, East Asian and  
179 Hispanic ancestry.

#### 180 *Rare coding variant mapping.*

181 To identify coding variants that may influence T2D risk by changing protein structures, we investigated  
182 predicted loss of function (pLoF) and missense variants in LD with the identified T2D lead variants  
183 (Supplementary Table 12). We identified 2 pLoF (*LPL* and *ANKDD1B*) and 45 missense variants in 47  
184 genes that were in LD with at-least one of the T2D lead SNPs ( $r^2 > 0.5$ , MVP reference panel in  
185 Europeans) and were associated at a P-value  $< 1.0 \times 10^{-4}$ . We also identified 9 missense variants that were  
186 either within 5 Mb of sentinel SNPs or in moderate to low LD ( $r^2 < 0.5$ ) and were associated with T2D at a  
187 P-value  $< 1.0 \times 10^{-4}$ . Of the 56 pLoF and missense variants, 14 missense variants were found to be the  
188 sentinel T2D SNPs and 19 variants were in LD with novel lead SNPs, and 37 variants were previously  
189 reported.

190 We then performed a genome-wide screen of all pLoF's (not bound by proximity to sentinel T2D  
191 lead variants) and missense variants available for analysis (Supplemental Table 13) and identified one

192 additional pLoF variant in the *CCHCR1* gene, whereas 37 novel missense variants were associated with  
193 T2D at a P-value threshold of  $5 \times 10^{-8}$ .

194 *Rare coding variant PheWAS.*

195 To understand biological pleiotropy and underlying mechanisms, we performed a PheWAS of the 3 pLoF  
196 variants associated with T2D in MVP participants of European ancestry (Table 5). These loci included  
197 *ANKDD1B* p.Trp480\*, *CCHCR1* p.Trp78\*, and *LPL* p.\*474Ser in the MVP, and were significantly associated  
198 with metabolic and inflammatory conditions. For example, *ANKDD1B* p.Trp480\* was associated with  
199 dyslipidemia, hypercholesterolemia, and diabetic neurological manifestations. *CCHCR1* p.Trp78\* was  
200 associated with type 1 diabetes, epistaxis, celiac disease, microscopic hematuria, and psoriatic  
201 arthropathy. Finally, the recent report by Klarin *et al.* includes a PheWAS of *LPL* p.\*474Ser in MVP<sup>14</sup>,  
202 which was associated with dyslipidemia, coronary atherosclerosis and other chronic ischemic heart  
203 disease.

204 *Transcriptome-wide association analyses.*

205 Common variants from the European T2D GWAS meta-analysis were used to evaluate the association of  
206 genetically predicted gene expression levels with T2D risk across 52 tissues including kidney and islet  
207 cells using S-PrediXcan<sup>15</sup> (Supplemental Table 8, Supplemental Figure 3). We identified 4,468 statistically  
208 significant gene-tissue combination pairs genetically predictive of T2D risk, of which 4,211 transcript  
209 eQTLs were in LD ( $r^2 > 0.5$ ) with T2D signals. We identified 873 genes in this analysis that would not have  
210 been identified by nearest-gene annotation alone. The strongest gene-tissue combination signals were  
211 for *NRAP* in the cerebellum and *TCF7L2* in the aortic artery.

212 We additionally used COLOC to identify the subset of significant genes where there was a high  
213 posterior probability that the set of model SNPs in the S-PrediXcan analysis for each gene were both  
214 causal for the expression and T2D. This analysis refined the results of the TWAS and excluded some

215 results that might be the consequence of LD between causal SNPs for gene expression and T2D. We  
216 detected 3,568 gene-tissue pairs where there was statistically significant association with T2D risk and  
217 high posterior probability ( $P_4 > 0.5$ ) of colocalization. The colocalized and significant results included 804  
218 genes. When comparing the 804 genes to the GWAS catalog mapped and reported genes for all prior  
219 studies of diabetes or diabetes complications, 687 had not been identified previously.

220 Hypergeometric enrichment analysis showed that most enriched gene expression signals were  
221 in the following tissues: cervical spinal cord, basal ganglia, glomerular kidney, tibial nerve, transformed  
222 fibroblasts, and skeletal muscle (Supplemental Table 15). A cross-section of the putative genes identified  
223 through transcriptome-wide analysis and the genes identified from the genome-wide coding variant  
224 lookup (Supplemental Table 12) identified the genes: *PCNT* p.Ile539Thr, *NMI* p.Leu16Ser, *TRIM66*  
225 p.His322Arg, *STARD3* p.Gln117Arg, and *ZNF641* p.Gln363Pro.

226 *Assessment of gene–drug relationships.*

227 Of the 991 genes identified in S-PrediXcan analyses, 54 genes have documented interactions with a total  
228 of 283 FDA-approved drugs and chemical compounds that do not have an indication for T2D treatment  
229 or reported ADE in diabetic patients using the SIDER database of drugs and side effects<sup>16</sup>. Using the  
230 Drug-Gene Interaction Database<sup>17</sup> (DGIdb version 3.0) a total of 322 gene-drug combinations were  
231 identified for which it is predicted that they would lower blood glucose based on direction of effect on  
232 T2D risk with increasing gene expression and drug action (activator or inhibitor)(Supplemental Table 14).  
233 Gene-drug combinations included several established T2D loci including *KCNJ11* targeted by 15  
234 compounds (e.g. sulfonylureas, glinides, and p-glycoprotein inhibitors), *SCNA3* targeted by 57  
235 compounds (e.g. anti-arrhythmics, anti-epileptics), *PIK3CB* targeted by 46 compounds (e.g. cancer  
236 drugs), *ACE* targeted by 36 compounds (e.g. angiotensin-converting enzyme [ACE] inhibitors), *HMGCR*  
237 targeted by 18 compounds (e.g. HMG-CoA reductase inhibitors), *PIK3C2A* targeted by 15 compounds

238 (anti-cancer drugs), *F2* targeted by 11 compounds (anti-coagulants), and *BLK* targeted by 9 compounds  
239 (protein kinase inhibitors).

240 The gene most significant in S-PrediXcan targeted by a non-antiglycemic medication was *PPARG*  
241 in EBV-transformed lymphocytes (Supplemental Table 8). The gene most significant in S-PrediXcan  
242 targeted by a drug with report of ADE in diabetic patients was *TH* in non-sun-exposed suprapubic skin.  
243 The gene most significant in S-PrediXcan targeted by an established anti-glycemic medication was  
244 *KCNJ11* in sun-exposed skin from the lower leg.

245 *Pathway and functional enrichment analysis.*

246 To explore whether our results recapitulate the pathophysiology of T2D, we performed gene-set  
247 enrichment analysis with all the variants using DEPICT ( $P < 1 \times 10^{-5}$ , Supplemental Table 16). MeSH-based  
248 analysis showed that several different adipose tissues and sites were enriched (abdominal subcutaneous  
249 fat, abdominal fat, adipose tissue, subcutaneous fat, and white adipose tissue). Finally, DEPICT analysis  
250 showed that the most significant gene-set involved the AKT2 subnetwork, lung cancer, the GAB1  
251 signalosome, protein kinase binding, signal transduction, and EGFR signaling (Supplemental Table 17).

252 *Genetic correlation between T2D and other phenotypes.*

253 Genome-wide genetic correlations of T2D were calculated with a total of 774 complex traits and  
254 diseases by comparing allelic effects using LD score regression (Online Methods). A total of 270  
255 significant associations were observed ( $P < 5.0 \times 10^{-8}$ , Supplementary Table 19). The strongest positive  
256 correlations were observed with waist circumference, overall health, BMI, and fat mass of arms, legs,  
257 body and trunk, hypertension, coronary artery disease, dyslipidemia, alcohol intake, years of education,  
258 wheezing, and cigarette smoking. There was also a strong negative correlation with years of education.

259

260 *T2D-related micro- and macrovascular outcomes.*

261 Using a genome-wide approach, we investigated SNP-T2D interaction effects associated with T2D-  
262 related vascular outcomes among European-descent MVP participants ( $P < 5 \times 10^{-8}$ , Online Methods,  
263 Table 3a-b). The analysis included a total case count of 67,403 for CKD, 56,285 for CHD, 35,882 for PAD,  
264 11,796 for acute ischemic stroke, 13,881 for retinopathy, and 40,475 for neuropathy. Several genome-  
265 wide significant interactions were identified where the genetic associations with T2D-related vascular  
266 outcomes were modified by T2D (Table 3a-b). We identified 2 loci for CHD (rs1831733 in 9p21 and  
267 rs602633 near *SORT1*) and 1 for CKD (rs34857077 in *UMOD*) for which the difference in the effect  
268 estimates between T2D strata was genome-wide significant ( $P < 5.0 \times 10^{-08}$ ) and at least one T2D-stratum  
269 was genome-wide significant as well. We additionally identified 1 locus for CHD (rs71039916 near  
270 *PDE3A*), 1 for CKD (rs2177223 near *TENM3*), 1 for PAD (rs3104154 in *PTDSS1*), 1 for neuropathy  
271 (rs78977169 near *NRP2*), 4 for retinopathy (rs76754787 nearby *GJA8*, rs10733997 in *SVILP2*, rs2255624  
272 near *SLC18A2*, and rs4132670 in *TCF7L2*) and 2 for acute ischemic stroke (rs491203 near *TMEM51*, and  
273 rs2134937 near *TRIQQ*) that showed a genome-wide significance for difference in effect estimates  
274 between the T2D strata and nominal significance ( $P < 0.001$ ) for at least one T2D stratum.

275 *Polygenic risk scores and T2D-related micro- and macrovascular outcomes*

276 Genome-wide polygenic risk scores (gPRS) for T2D were calculated in Europeans based on the T2D effect  
277 estimates from the previously reported DIAMANTE consortium<sup>4</sup> and then categorized into deciles (Table  
278 4a-b). As expected, participants with the highest T2D gPRS scores (90-100% T2D gPRS percentile)  
279 showed the highest risk for T2D (OR = 5.21, 95% CI 4.94-5.49, Supplemental Figure 5) when compared to  
280 the reference group (0-10% T2D gPRS percentile) in a cross-sectional study design.

281 We evaluated whether the T2D gPRS was associated with the risk of micro- and macrovascular  
282 outcomes in an analysis restricted to participants with T2D. The P-value are calculated using gPRS as a

283 continuous exposure and odds ratios are shown by contrasting the top to the bottom gPRS decile (Figure  
284 2 and Table 4a-b). The T2D gPRS was more strongly associated with microvascular than macrovascular  
285 outcomes, in particular with retinopathy, but also with neuropathy and CKD. For macrovascular  
286 outcomes, T2D gPRS was associated with the risk of PAD, but not with the risk of CHD or acute ischemic  
287 stroke.

## 288 Discussion

289 We report the discovery of 318 novel autosomal and X-chromosome variants associated with T2D  
290 susceptibility in a large multi-ethnic T2D study. Furthermore, we observed 13 variants associated with  
291 differences in T2D-related micro- and macrovascular outcomes between diabetic and non-diabetics. The  
292 substantial locus discovery was achieved by combining data from several large-scale biobanks and  
293 consortia, where the MVP data constituted over 40% of all T2D cases. Furthermore, we present the  
294 largest cohort of African Americans including over 56K subjects, substantially greater than any African-  
295 specific T2D study published to date.

296 Analyses of coding variants identified 44 variants for T2D, including three pLoF variants in *LPL*,  
297 *ANKDD1B* and *CCHCR1*. 804 putative causal genes at both novel and previously reported loci were  
298 identified and 54 genes were found to be possible targets for FDA-approved drugs and chemical  
299 compounds. Our SNP-T2D interaction analyses identified several loci where the association between a  
300 genetic variant and a vascular outcome differed between people with T2D as compared to those  
301 without. We further found that a high polygenic risk for T2D strongly increased the risk for retinopathy  
302 in patients with T2D, and also for CKD, neuropathy, and PAD.

303 T2D is highly prevalent in people of African ancestry; however there are a total of three  
304 published T2D GWAS reports in this ancestral group with only 4 definitely detected loci<sup>18,19,20</sup>. In our  
305 study with over 56K participants of recent African ancestry, we report 4 novel loci for T2D that are solely

306 observed in this ancestral group, including one that is located on chromosome X. Of the previously  
307 reported loci, only rs3842770 (INS-IGF2) was replicated here. The reported HLA-B variant rs2244020<sup>18</sup>  
308 did not replicate in our study; but we did observe a significant association with another SNP in the HLA  
309 region (rs10305420, OR 1.15,  $P = 8.5 \times 10^{-9}$ ). We did not replicate the association with the variant  
310 rs7560163<sup>20</sup>. Finally, 1 locus (rs73284431) that was recently identified in a large study conducted in Sub-  
311 Saharan African countries<sup>19</sup> failed to replicate in our study consisting of African Americans despite  
312 comparable minor allele frequencies (9% vs 10%). Finally, we observed that one *SLC30A8* variant  
313 showed a very prominent T2D effect in African Americans that was absent in other populations; mouse  
314 studies have shown that the human R138X LoF variant in *SLC30A8* results in increased insulin secretory  
315 capacity<sup>21</sup>.

316         The sole presence of a coding variant near a tagging SNP does not constitute enough evidence  
317 to infer a causal association. However, recent exome-array genotyping of over 350K subjects identified  
318 40 coding variants associated with T2D, of which 26 mapped to near known risk-associated loci<sup>22</sup>.  
319 Similarly, an exome sequencing study in over 40K participants reported 15 variants associated with T2D,  
320 of which only 2 were not previously reported by GWAS<sup>13</sup>. Sequencing efforts are indispensable for  
321 identifying causal variants and genes related to disease, as well as providing insight into the  
322 contributions of ultra-rare alleles, but have also substantiated the value of array-based association  
323 studies.

324         Our transcriptome-wide analyses identified 804 putatively causal genes, including 54 genes that  
325 appear to be regulated by approved drugs and 687 genes that have not been previously reported. Some  
326 of these genes are already well established for T2D etiology (e.g. *KCNJ11*). Except for skeletal muscle,  
327 the tissues that showed strongest associations are not known to be of importance in T2D etiology. This  
328 raises the hypothesis that the eQTL associations are universal and not tissue dependent; if the gene is  
329 expressed in the respective tissue at reasonable levels an association will be detected. We did not

330 observe any significant association in the alpha and beta islet cells, which could be the result of the small  
331 sample size (e.g. 30 alpha cells and 19 beta cells). In addition, whole islet transcriptomes are notoriously  
332 variable due to the large differences in islet composition among humans, and a few transcripts make up  
333 half the transcriptome<sup>23</sup>.

334 Of particular clinical importance, we identified several genes which are therapeutic targets for  
335 medications in patients that are treated for cardiometabolic conditions. We identified two genes, *SCN3A*  
336 and *SV2A* whose expression is modified by anti-epileptic agents, and evidence exists showing that anti-  
337 epileptic agents may influence glucose regulation. A randomized-controlled trial has reported that the  
338 anticonvulsant valproic acid lowers blood glucose concentrations<sup>24</sup>. The information from the gene-drug  
339 screen may facilitate future drug repurposing screens.

340 DEPICT enrichment analysis identified *AKT2* subnetwork gene set to be show the highest  
341 association with T2D. Of interest is that *AKT2* is critical to insulin signaling and not beta-cell function.  
342 The majority of the early era T2D GWAS studies<sup>25</sup> predominantly identified genetic variants that alter  
343 T2D risk through reduced beta-cell function, such as *KCNJ11*, *HHEX*, *SLC30A8*, *CDKAL1*, *TCF7L2*,  
344 *CDKN2A/2B*, and *IGF2BP2*. However, as the study sample size have substantially increased and the  
345 number of T2D-associated variants is approaching the 1.000 number mark, the cumulative effect of  
346 genetic variants on T2D is pointing towards a predominant role for insulin resistance.

347 When we evaluated polygenic risk scores and T2D-related outcomes, we observed that among  
348 vascular outcomes, the T2D gPRS was most significantly associated with retinopathy. It is possible that  
349 the use of the T2D gPRS provides an opportunity to identify patients who are at the highest risk of  
350 developing microvascular complications, such as retinopathy. Using the T2D gPRS, we observed  
351 significant associations with other T2D-related outcomes such as CKD, PAD, and neuropathy. Studies at



352 specific loci using both common and rare coding variants will be required to understand pathways  
353 leading to T2D-related vascular outcomes.

354 In a SNP-T2D interactions analysis on T2D-related vascular outcomes we identified 13 loci where  
355 the effect on outcome was different between the strata of T2D, of which 3 occurred at previously  
356 established variants and 10 had not been previously reported. Our findings have clinical translational  
357 potential for risk-stratification and identify diabetic patients who are predisposed to develop  
358 subsequent vascular outcomes and present therapeutic opportunities to attenuate the risk of diabetes  
359 progression in individuals with T2D.

360 For T2D-related retinopathy, four variants were found to have different effect sizes between  
361 people with and without T2D. The strongest signal for interaction in relation to retinopathy was  
362 observed for *GJA8*. Deletion of this gene has been associated with eye abnormalities and retinopathy of  
363 prematurity in premature infants, inherited cataracts, visual impairment and cardiac defects and eye  
364 abnormalities<sup>26-28</sup>. *TCF7L2* is a known diabetes locus and its association with progression to retinopathy  
365 has been previously established<sup>29</sup>. *SLC18A2* is expressed in adult retina and retinal pigment epithelium  
366 tissues<sup>30</sup>; this gene is involved in the transport of monoamines into secretory vesicles for exocytosis<sup>31</sup>.  
367 *SVILP1* has been previously shown to be associated with thiamine (vitamin B1) prescription, which is  
368 frequently prescribed to people with blurry vision<sup>32</sup>.

369 For chronic kidney disease, two loci, *UMOD* and *TENM3*, were identified for gene-T2D  
370 interaction effects. *UMOD* encodes for uromodilin which is exclusively produced by the kidney tubule  
371 where it plays an important role in kidney and urine function<sup>33</sup>. A large-scale study in over 133K  
372 participants has shown that the serum creatinine-lowering allele in *UMOD* (rs12917707) is more  
373 prevalent in diabetic individuals with CKD as compared to diabetic participants without CKD<sup>34</sup>. Variation  
374 in *TENM3* has been associated with cholangitis and kidney disorders in the UK Biobank<sup>35</sup>.

375 SNP-T2D interaction analysis of neuropathy identified one locus, *NRP2*. *NRP2* encodes for  
376 neuropilin-2 which is an essential cell surface receptor involved in VEGF-dependent angiogenesis and  
377 sensory nerve regeneration<sup>36,37</sup>.

378 For coronary heart disease, we identified several SNP-T2D interactions. Variation at 9p21 has  
379 been reported previously for CHD and T2D. *SORT1* is a lipid-associated locus; in our analyses, allelic  
380 variation at this locus that decreases CHD risk and decreases lipids conferred a stronger protection in  
381 people with T2D compared to those without T2D. Coupled with findings in mice that identified *SORT1* as  
382 a novel target of insulin signaling<sup>38</sup>, our findings raise the hypothesis that *SORT1* may contribute to  
383 altered hepatic apoB metabolism under insulin-resistant conditions.

384 The SNP rs71039916 is located nearby *PDE3A*, and collocates with a SNP (rs3752728,  $D' = 0.867$ ,  
385  $r^2 = 0.08$ ) that is associated with diastolic blood pressure<sup>39,40</sup>. As a phosphodiesterase that reduces cAMP  
386 levels, the PDE3A protein limits protein kinase A/cAMP signaling, and has been shown to affect  
387 proliferation of vascular smooth muscle cells<sup>41</sup>. Cell line research has shown that cAMP levels might  
388 impact the regulation of insulin secretion in pancreatic  $\beta$ -cells<sup>42</sup>, and more recent gene ablation studies  
389 in mice have established that cAMP/CREB signaling controls the insulinotropic and anti-apoptotic effects  
390 of GLP-1 signaling in adult mouse  $\beta$ -cells<sup>43</sup>. Subcutaneous adipose tissue of patients with T2D show  
391 increased PDE activity, and inverse correlations between total PDE3 activity and BMI have been  
392 reported in adipocytes<sup>44</sup>.

393 We have conducted the largest discovery study for T2D to date, including over 220K T2D cases  
394 and 1.2 million controls. Over 21% of our discovery sample comprised of non-European participants; our  
395 African American sample included over 56K subjects. A unique strength in our study is the  
396 comprehensive individual level phenotype data available for analyzing T2D and related micro- and

397 macrovascular outcomes. This allowed us to test for genetic interaction instead of evaluating effect  
398 differences between strata using summary statistics.

399           In summary, we have identified 318 novel genetic variants associated with T2D risk and T2D-  
400 related vascular outcomes, including 3 population-specific autosomal loci in African Americans, 8  
401 chromosome-X variants, plus an additional 13 variants associated with differences in T2D-related micro-  
402 and macrovascular outcomes across diabetic stratum. Coding variant analyses and transcriptome wide  
403 analyses have identified many putative causal genes that could be pursued in functional mechanistic  
404 studies and provide an updated map of effects for gene-tissue pairs for T2D risk. Our gene-drug analyses  
405 provide a genetic basis to guide future drug repurposing studies. Lastly, our SNP-T2D interaction  
406 analyses elucidate differences in pathogenetic mechanisms of T2D-related vascular outcomes with  
407 potential clinical implications for preventing development of microvascular complications in T2D.

408

409 **Online Methods**

410 We conducted a large-scale multi-ethnic autosomal and X-chromosome T2D GWAS of common variants  
411 in over 1.4 million participants. We subsequently conducted analyses to facilitate the prioritization of  
412 these individual findings, including transcriptome-wide predicted gene expression for T2D, secondary  
413 signal analysis, T2D-related vascular outcomes analysis using SNP-T2D interaction analysis, coding  
414 variant mapping, phenome-wide association analyses of pLoF variants, and a drug repurposing screen.

415 *Discovery cohort.*

416 The Million Veteran Program (MVP) is a large cohort of fully consented veterans of the United States  
417 military forces recruited from 63 participating Department of Veterans Affairs (VA) medical facilities<sup>3</sup>.  
418 Recruitment started in 2011, and all veterans were eligible for participation. Compared with the general  
419 population, the Million Veteran Program is overrepresented with participants of male gender, but the  
420 study is representative of the US population in terms of race and ethnicity. This study analyzed clinical  
421 data through July 2017 for participants who enrolled between January 2011 and October 2016. Across  
422 ancestries, the average age at study enrollment ranged from 56.1 for Asian to 68.2 for European  
423 participants (Supplementary Table 3). Average body mass index (BMI) ranged from 28.5 for Asians to  
424 30.8 for African Americans. The proportion of males ranged from 87.2% for African Americans to 93.9%  
425 for Asians. The prevalence of T2D was 35.5% for Europeans, 36.4% for Asians, 42.1% for Hispanics, and  
426 43.6% for African Americans. All MVP study participants provided blood samples for DNA extraction and  
427 genotyping, and completed surveys about their health, lifestyle, and military experiences. Consent to  
428 participate and permission to re-contact was provided after counseling by research staff and mailing of  
429 informational materials. Study participation includes consenting to access to the participant's electronic  
430 health records for research purposes, data that captures a median follow-up time of 10.0 years at time  
431 of study enrollment. Each veteran's electronic health care record is integrated into the MVP  
432 biorepository, including inpatient International Classification of Diseases (ICD-9-CM and ICD-10-CM)

433 diagnosis codes, Current Procedural Terminology (CPT) procedure codes, clinical laboratory  
434 measurements, and reports of diagnostic imaging modalities. Researchers are provided data that is de-  
435 identified except for dates, and do not have the ability or authorization to link these details with a  
436 participant's identity. Blood samples are collected by phlebotomists and banked at the VA Central  
437 Biorepository in Boston, where DNA is extracted and shipped to two external centers for genotyping.  
438 The Million Veteran Program received ethical and study protocol approval from the VA Central  
439 Institutional Review Board (cIRB) in accordance with the principles outlined in the Declaration of  
440 Helsinki.

441 Genotyping: DNA extracted from buffy coat was genotyped using a custom Affymetrix Axiom biobank  
442 array. The MVP 1.0 genotyping array contains a total of 723,305 SNPs, enriched for 1) low frequency  
443 variants in African and Hispanic populations, and 2) variants associated with diseases common to the VA  
444 population<sup>3</sup>.

445 Genotype quality-control: The MVP genomics working group applied standard quality control and  
446 genotype calling algorithms to the data in two batches using the Affymetrix Power Tools Suite (v1.18).  
447 Standard quality control pipelines were used to exclude duplicate samples, samples with more  
448 heterozygosity than expected, samples with an excess (> 2.5%) of missing genotype calls and samples  
449 with discordance of genetically inferred sex versus self-report. We excluded related individuals (halfway  
450 between second- and third-degree relatives or closer) as measured by the KING software<sup>45</sup>. Before  
451 imputation, variants that were poorly called or that deviated from their expected allele frequency based  
452 on reference data from the 1000 Genomes Project were excluded<sup>46</sup>. After prephasing using EAGLE v2<sup>47</sup>,  
453 genotypes from the 1000 Genomes Project phase 3, version 5 reference panel were imputed into MVP  
454 participants via Minimac3 software<sup>48</sup>. The top 30 principal components were computed using FlashPCA<sup>49</sup>  
455 on a genotype dataset that included all MVP participants and an additional 2,504 individuals from 1000  
456 Genomes. These 30 PCs were then used for the unification of self-reported race/ancestry and

457 genetically inferred ancestry to compose ancestral groups used for stratification in subsequent  
458 association analyses<sup>50</sup>.

459 Race and ethnicity: Information on race (Europeans, African Americans, Asians and Native Americans)  
460 and ethnicity (Hispanic, yes or no) was obtained based on self-report through centralized VA data  
461 collection methods using standardized survey forms, or through the use of information from the VA  
462 Corporate Data Warehouse or Observational Medical Outcomes Partnership data, when information  
463 from self-report survey was missing. Even though self-reported race/ethnicity was missing in 3.67% of  
464 study participants, 39.4% of participants had some form of discordant information between the various  
465 sources of which the data was extracted. Race and ethnicity categories were merged to form the  
466 following race or ancestral groups: Europeans, African Americans, Hispanics, and Asians using a unifying  
467 classification algorithm based on self-identified race/ethnicity and genetically inferred ancestral  
468 information, termed HARE (Harmonized Ancestry and Race/Ethnicity)<sup>50</sup>. Using this approach, of the total  
469 of 351,820 genotyped individuals all but 6,257 (1.78%) were assigned to one of the four ancestral  
470 groups.

471 Phenotype classification: ICD-9-CM diagnosis codes from electronic health care records were available  
472 for MVP participants from as early as 1998. Participants were classified as a T2D case if they had 2 or  
473 more T2D-related diagnosis codes (ICD-9-CM 250.2x) from VA or fee basis inpatient stays or face-to-face  
474 primary care outpatient visits in the 731 days before the enrollment date up to July 1<sup>st</sup> of 2017,  
475 excluding those with co-occurring diagnosis codes for T1D (250.1x), secondary or other diabetes or a  
476 medical condition that may cause diabetes (249.xx). Participants were selected as controls if they had no  
477 ICD-9-CM diagnosis code for type 1, type 2, or secondary diabetes mellitus up to July 2017.

478 For T2D-related vascular outcomes, the following definitions were used: CHD, at least one admission to  
479 a VA hospital with discharge diagnosis of admission for myocardial information, or at least one  
480 procedure code for revascularization (coronary artery bypass grafting, percutaneous coronary

481 intervention), or at least 2 ICD-9-CM codes for CAD (410 to 414) registered on at least 2 separate  
482 encounters. Subjects were classified as having PAD if they had at least two of ICD-9-CM codes or CPT  
483 codes as outlined in the report of Klarin *et al.*<sup>14</sup>, or having one code and at least two visits to a vascular  
484 surgeon within a 14 month period. Acute ischemic stroke was defined if at least 1 ICD-9-CM discharge  
485 diagnosis code for stroke excluding head injury or rehab (433.x1, 434 [excluding 434.x0], and 436) was  
486 present<sup>51</sup>. CKD was classified as an estimated glomerular filtration rate <60 mL/min-1.73 m<sup>-2</sup> on 2  
487 separate measurements 90 days apart, or ICD-9-CM diagnosis codes for chronic renal failure (585)  
488 and/or a history of kidney transplantation (ICD-9-CM V42)<sup>52</sup>; Neuropathy was defined using the  
489 following ICD-9-CM diagnosis codes: diabetic neuropathy (356.9, 250.6), amyotrophy (358.1), cranial  
490 nerve palsy (951.0, 951.1, 951.3), mono-neuropathy (354.0-355.9), Charcot's arthropathy (713.5),  
491 polyneuropathy (357.2), neurogenic bladder (596.54), autonomic neuropathy (337.0, 337.1), orthostatic  
492 hypotension (458). Retinopathy was defined using ICD-9-DM diagnosis codes for: T2D with ophthalmic  
493 manifestations (250.50, 250.52), retinal detachments and defects (361.0, 361.1), disorders of vitreous  
494 body (379.2), other retinal disorders (362.0, 362.1, 362.3, 362.81, 362.83, 362.84), excluding ICD-9-CM  
495 codes associated with macular degeneration (362.5).

496 MVP analysis: We tested imputed SNPs that passed quality control (e.g. HWE > 1.0x10<sup>-10</sup>, INFO > 0.3, call  
497 rate > 0.975) for association with T2D through logistic regression assuming an additive model of variants  
498 with MAF > 0.1% in Europeans, and MAF > 1% in African Americans, Hispanics and Asians using PLINK2a  
499 software<sup>53</sup>. Covariates included age, gender, and 10 principal components of genetic ancestry.

500 Other studies: Summary statistics available from previous reports in the DIAMANTE Consortium<sup>4</sup>,  
501 Biobank Japan<sup>7</sup>, Penn Medicine Biobank<sup>5</sup>, Malmö Diet and Cancer Study<sup>8</sup>, MedStar/PennCath studies<sup>9</sup>,  
502 and the Pakistani Genomic Resource<sup>6</sup> were obtained for meta-analysis (Supplemental Table 2). All  
503 cohort were imputed using the 1000 Genomes Project phase 3, version 5 reference panel with exception  
504 of the DIAMANTE consortium where genotype calls were imputed using the Haplotype Reference

505 Consortium reference panel<sup>54</sup>. Briefly, following central and study-specific quality control protocols, an  
506 additional 917,392 Europeans, 2,647 African Americans, and 213,834 Asians were available for T2D  
507 meta-analysis. Only SNPs with ancestry-specific MAF > 1% in these studies were used. Within each study  
508 a logistic regression model was used where T2D was set as the dependent variable, imputed SNP as the  
509 independent variable, and analyses were adjusted for age, gender, and the top ten principal  
510 components of genetic ancestry.

511 Meta-analysis: We aggregated association summary statistics from the above mentioned studies to  
512 perform ancestry-specific and multi-ethnic meta-analysis. The association summary statistics for each  
513 analysis were meta-analyzed in a fixed-effects model using METAL with inverse-variance weighting of  
514 log odds ratios<sup>55</sup>. From the meta-analysis, all variants were extracted that passed quality control.  
515 Between-study allelic effect size heterogeneity was assessed with Cochran's Q statistic as implemented  
516 in METAL. Variants were considered genome-wide significant if they passed the conventional p-value  
517 threshold of  $5.0 \times 10^{-8}$ . We excluded variants with a high amount of heterogeneity ( $I^2$  statistic > 75%)  
518 across the four evaluated ancestral groups.

519 Novel loci: Novel loci were defined as those in which the lead variant was not in LD or physically nearby  
520 (500 Kb) to a previously reported lead GWAS variant(s). For each locus, we first searched  $\pm 500$  Kb  
521 surrounding the lead SNP to ensure that potential long-range genetic influences were assessed.

522 Chromosome-X analysis: X chromosome genotypes were processed separately from autosomal  
523 genotypes. During prephasing and imputation an additional flag of -chrX was added. In post-imputation  
524 stage, the XWAS QC pipeline was employed to remove variants in the pseudo-autosomal regions,  
525 variants that were not in HWE in females ( $P > 1.0 \times 10^{-6}$ ), variants with differential allele frequencies, and  
526 variants with differential missingness ( $p < 10^{-7}$ ) between males and female controls (Supplemental  
527 Figure 2)<sup>56</sup>. For each ancestry-specific subset, we performed sex-stratified analysis where dosages



528 (number of chromosome copies) for the X-chromosome in T2D cases are equivalent to controls within  
529 each sex stratum. For the meta-analysis of sexes, differences in dosage compensation should be  
530 considered between males (with one X chromosome) and females (with two X chromosomes). In a  
531 separate verification analysis we performed a chromosome-X association analysis on dosage data using  
532 PLINK (--xchr-model) which produced consistent results compared with analysis of best-guess data  
533 where the X chromosome was coded as 0/2 for males instead of 0/1. The output from sex-stratified  
534 chromosome-X analyses were first meta-analyzed into a multi-ethnic sex-stratified analysis. Then, the  
535 multi-ethnic results from males and multi-ethnic results from females were meta-analyzed, where none  
536 of the analyzed variants was detected using the Cochran test for heterogeneity ( $P < 5.0 \times 10^{-8}$ ). Results  
537 presented include overall effect estimates, male-specific effect estimates, female-specific estimates, and  
538 the heterogeneity p-value (Supplementary Table 13).

539 *Secondary signal analysis.*

540 GCTA<sup>57</sup> was used to conduct conditional analyses to detect ancestry-specific distinct association signals  
541 at each of the lead SNPs utilizing the meta-analyzed GWAS summary statistics in Europeans and African  
542 Americans. Race-stratified MVP cohorts (197,066 Europeans and 53,445 African Americans) were used  
543 to model LD patterns between variants. The reference panel of genotypes consisted of the variants with  
544 allele frequencies  $> 0.1\%$  in Europeans and  $> 1\%$  in African Americans that passed quality control criteria  
545 in the MVP-specific T2D GWAS (INFO  $> 0.3$ , HWE  $P > 1.0 \times 10^{-10}$ , call rate  $> 0.975$ ). For each lead SNP,  
546 conditionally independent variants that reached locus-wide significance ( $P < 1.0 \times 10^{-5}$ ) were considered  
547 as secondary signals of distinct association. If the minimum distance between any distinct signals from  
548 two separate loci was less than 500 Kb, we performed additional conditional analysis including both  
549 regions and reassessed the independence of each signal. Finally, the predicted conditionally  
550 independent variants were tested in a logistic regression model in the MVP study only to empirically  
551 validate the signal, and results are shown in Supplemental Tables 7 and 10.

552 *Coding variant mapping.*

553 All imputed variants in MVP were evaluated with Ensemble variant effect predictor<sup>58</sup>, and all predicted  
554 LoF and missense variants were extracted. The LD was calculated with established variants, and in a  
555 second round of analysis the effect of the missense variant was calculated conditioning on the lead SNP  
556 to assess how much residual variance the SNP explains in T2D risk. A p-value of 0.05 was considered as  
557 statistically significant.

558 *S-PrediXcan and colocalization analyses.*

559 Genetically predicted gene expression and its association with T2D risk was estimated using S-  
560 PrediXcan<sup>15</sup>. Input included meta-analyzed summary statistics from the European T2D GWAS for  
561 common variants and reference eQTL summary statistics for 52 tissues including 48 tissues from GTEx<sup>59</sup>,  
562 2 cell types in kidney tissue (glomerulus and tubulus)<sup>60</sup>, and 2 cell types in pancreatic islet tissue (alpha  
563 and beta)<sup>61</sup>. Analyses incorporated genotype covariance matrices based on 1000 Genomes<sup>46</sup> European  
564 populations to account for LD structure. Colocalization analysis was performed to address the issue of  
565 LD-contamination in S-PrediXcan analyses<sup>62</sup>. Input data were identical to those evaluated by S-PrediXcan  
566 and colocalization was restricted to only variants included in the S-PrediXcan gene<sup>63</sup>. The output is  
567 shown in Supplemental Table 8.

568 *Phenotypic variance explained by SNPs.*

569 The MVP European cohort (69,869 T2D cases and 127,197 controls) was used to calculate the variance  
570 explained by the 558 genome-wide-significant sentinel SNPs from the multi-ethnic meta-analysis. A  
571 logistic regression model was performed assuming additive effects where T2D was set as the dependent  
572 variable, and the sentinel SNPs as independent variables, adjusting for sex, age, and 10 principal  
573 components. The baseline model included age, gender and 10 principal components. The variance  
574 explained was calculated with the  $R^2$  statistic, calculated as  $1 - (\text{residual deviance} / \text{null deviance})$ .

575 *Phenome-wide association analysis.*

576 For the three LoF variants that were identified using coding variant analysis, we performed a PheWAS  
577 study<sup>64</sup> to fully leverage the diverse nature of the Million Veteran Program as well as the full catalog of  
578 relevant ICD-9-CM diagnosis and CPT procedure codes (Supplementary Table 18). Of genotyped  
579 veterans, participants were included in the PheWAS analysis if their respective electronic health record  
580 reflected two or more separate encounters in the VA Healthcare System in each of the two years prior  
581 to enrollment in MVP. Using this method, a total of 277,531 veterans spanning 21,209,658 available ICD-  
582 9 diagnosis codes were available for PheWAS analysis. We restricted our analysis on the subgroup of  
583 197,066 European participants. Diagnosis and procedure codes were collapsed to clinical disease groups  
584 and corresponding controls using predefined groupings<sup>65</sup>. Phenotypes were required to have a case  
585 count over 25 in order to be included in the PheWAS analysis, and a multiple testing thresholds for  
586 statistical significance was set to  $P < 2.8 \times 10^{-5}$  (Bonferroni method). Each of the previously unpublished  
587 LoF variants (ANKDD1B p.Trp480\* and CCHCR1 p.Trp78\*) were tested using logistic regression adjusting  
588 for age, sex, and 10 principal components in an additive effects model using the PheWAS R package in R  
589 v3.2.0<sup>66</sup>. The results from these analyses are reported as odds ratios, in which the estimate is the  
590 average change in odds of the PheWAS trait per weighted T2D-increasing allele (Supplementary Table  
591 18, Supplementary Figure 4).

592 *Analysis of T2D-related outcomes.*

593 Genetic data on European participants was separately analyzed using outcomes as a binary outcome,  
594 and T2D as an interaction variable with SNPs using interaction analysis with robust variance to reduce  
595 effect heteroscedacity (e.g. unequal variance between strata) using SUGEN software (v8.8)<sup>67</sup>. We  
596 evaluated the interaction between SNP and presence of T2D status using an interaction term for the two  
597 independent variables. Due to the binary nature of the outcome, the standard output from the

598 interaction effect estimate are interpreted on a multiplicative scale, e.g., the departure from the  
599 product of the two independent effects. To obtain interaction on an additive scale (e.g. departure from  
600 the sum of the independent effects), we calculated the relative excess risk due to interaction (RERI)  
601 metric, a well-known analytic method in classic epidemiologic literature<sup>68</sup>. In case-control studies using  
602 the linear additive odds-ratio model as proposed by Richardson and Kaufman<sup>68</sup> in our study has the form  
603 of:

$$604 \quad Odds = e^{\beta_0}(1 + \beta_1 \cdot SNP + \beta_2 \cdot T2D + \beta_3 \cdot SNP \cdot T2D)$$

605 In which the coefficient  $\beta_3$  measures the departure from additivity of exposure effect on an odds ratio  
606 scale; that is

$$607 \quad RERI_{OR} = \beta_3 = OR(SNP \cdot T2D) + OR(\overline{SNP} \cdot T2D) - OR(SNP \cdot \overline{T2D}) + 1$$

608 where  $\overline{SNP}$  and  $\overline{T2D}$  note the absence of the respective covariates.

609 In contrast to the standard exponential odds model, where the effects of explanatory variables are  
610 additive on an exponential scale, we performed analysis using a linear odds model, in order to quantify  
611 the excess odds per unit of the given explanatory variables on the outcome. In this model, the excess  
612 relative risk due to interaction is an estimate of the excess odds on a linear scale due to the interaction  
613 between two explanatory variables (in our case, T2D state and genotype dosage of the tested variant).  
614 In the SNPxT2D interaction analysis we used a significance threshold of  $P < 5.0 \times 10^{-08}$  to denote variants  
615 that statistically different effect sizes between participants with T2D as compared those without. An  
616 additional filter was applied, and variants for which the effect size in at least one of the two T2D strata  
617 was nominally significant at  $P < 0.001$  were included. Manhattan plots and the table are used to  
618 represent the interaction coefficients on this scale.

619

620 *Polygenic risk scores and risk of T2D and related outcomes.*

621 We constructed a genome-wide polygenic risk score (gPRS) for T2D in the MVP participants of European  
622 ancestry by calculating a linear combination of weights derived from the Europeans in the DIAMANTE  
623 Consortium<sup>4</sup> using the prune and threshold method in PRSice software<sup>69</sup>. After an initial sensitivity  
624 analysis, the  $r^2$  threshold for pruning was set to 0.8, and the P-value for significance threshold was set to  
625 0.05. The gPRSs were divided into deciles and the risk of T2D was assessed using a logistic regression  
626 model using the lowest decile as a reference (e.g. the 10% of participants with lowest of T2D gPRS),  
627 together with the potential confounding factors of age, gender, BMI, and the first 10 principal  
628 components of European ancestry. An additional outcomes analysis was performed to evaluate to what  
629 extent a T2D gPRS is predictive of T2D-induced morbidities. The dataset was restricted to subjects with  
630 T2D, and a stratum-restricted T2D gPRS deciles were generated. Logistic regression models were applied  
631 where the micro- and macrovascular conditions were modeled as outcomes, and independent variables  
632 included strata-restricted gPRS deciles, age, gender, and the first 10 principal components of European  
633 ancestry. The data were visualized using shape-plots.

634 *Heritability estimates and genetic correlations with other complex traits and diseases.*

635 LD-score regression was used to estimate the heritability coefficient, and subsequently population and  
636 sample prevalence estimates were applied to estimate heritability on the liability scale<sup>70</sup>. A genome-  
637 wide genetic correlation analysis was performed to investigate possible co-regulation or a shared  
638 genetic basis between T2D and other complex traits and diseases. Pairwise genetic correlation  
639 coefficients were estimated between the meta-analyzed T2D GWAS summary output in Europeans and  
640 each of 774 precomputed and publicly available GWAS summary statistics for complex traits and  
641 diseases by using LD score regression through LD Hub v1.9.3 (<http://ldsc.broadinstitute.org>). Statistical  
642 significance was set to a Bonferroni-corrected level of  $P < 6.5 \times 10^{-5}$ .

643 *Enrichment and pathway analyses.*

644 Tissue enrichment for S-PrediXcan results was evaluated by calculating exact P-values for under- or over-  
645 enrichment based on the cumulative distribution function of the hypergeometric distribution. The  
646 Bonferroni-corrected threshold for significance was  $P < 0.001$  considering evaluation of 52 tissues.  
647 Enrichment analyses in DEPICT<sup>71</sup> were conducted using genome-wide significant ( $P < 5.0 \times 10^{-8}$ ) T2D  
648 GWAS lead SNPs. DEPICT is based on predefined phenotypic gene sets from multiple databases and  
649 Affymetrix HGU133a2.0 expression microarray data from >37k subjects to build highly-expressed gene  
650 sets for Medical Subject Heading (MeSH) tissue and cell type annotations. Output includes a P-value for  
651 enrichment and a yes/no indicator of whether the FDR q-value is significant ( $P < 0.05$ ). Tissue and gene-  
652 set enrichment features were considered.

653 *Evaluation of drug classes for genes with associations with gene expression.*

654 To identify drug-gene pairs that may be leads for repurposing or may be attractive leads for novel  
655 inhibitory drugs, we identified drugs targeting genes whose predicted expression was significantly  
656 associated with T2D risk in S-PrediXcan analyses and which we predicted would lower blood glucose  
657 based on direction of effect on T2D risk with increasing gene expression and drug action (activator or  
658 inhibitor). Medications with a primary indication for diabetes and medications with adverse drug events  
659 for diabetic patients were evaluated using the SDe Effect Resource (SIDER)<sup>16</sup>. Medications targeting  
660 genes were queried using DGIdb<sup>17</sup>. These drug targets represent a set of genes that are both likely to be  
661 involved in glucose regulation in one or more tissues and can be targeted by drugs. Genes and  
662 medications identified in this analysis are presented in Supplementary Table 14.

663

664

665 **Acknowledgements**

666 This research is based on data from the Million Veteran Program, Office of Research and Development,  
667 Veterans Health Administration and was supported by award no. MVP000. This publication does not  
668 represent the views of the Department of Veterans Affairs, the US Food and Drug Administration, or the  
669 US Government. This research was also supported by funding from: the Department of Veterans Affairs  
670 award I01-BX003362 (P.S.T. and K.M.C) and the VA Informatics and Computing Infrastructure (VINCI) VA  
671 HSR RES 130457 (S.L.D) B.F.V. acknowledges support for this work from the NIH/NIDDK (DK101478), the  
672 NIH/NHGRI (HG010067) and a Linda Pechenik Montague Investigator award. K.M.C, S.M.D, J.M.G, C.J.O,  
673 L.S.P, and P.S.T. are supported by the VA Cooperative Studies Program. S.M.D. is supported by the  
674 Veterans Administration [IK2-CX001780]. D.K. is supported by the National Heart, Lung, and Blood  
675 Institute of the National Institutes of Health [T32 HL007734]. L.S.P. is supported in part by VA awards  
676 I01-CX001025, and I01CX001737, NIH awards R21DK099716, U01 DK091958, U01 DK098246,  
677 P30DK111024, and R03AI133172, and a Cystic Fibrosis Foundation award PHILL12A0. We thank all study  
678 participants for their contribution. Data on T2D have been contributed by investigators from DIAMANTE  
679 Consortium, Biobank Japan, Malmö Diet and Cancer Study, PennCath, MedStar, Pakistan Genomic  
680 Resource, Penn Medicine Biobank, and Regeneron Genetics Center. Data on stroke were provided by  
681 MEGASTROKE investigators, and data on CKD have been contributed by CKDgen investigators. Data on  
682 alpha and beta islet cells have been contributed by the HPAP Consortium. Data on coronary artery  
683 disease have been contributed by the CARDIoGRAMplusC4D investigators.

684

685 **Competing Interests**

686 None of the sponsors of the following authors had a role in the design and conduct of the study;  
687 collection, management, analysis, and interpretation of the data; and preparation, review, or approval  
688 of the manuscript. D.S. has received support from the British Heart Foundation, Pfizer, Regeneron,

689 Genentech, and Eli Lilly pharmaceuticals. L.S.P. has served on Scientific Advisory Boards for Janssen, and  
690 received research support from Abbvie, Merck, Amylin, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche,  
691 Abbvie, Vascular Pharmaceuticals, Janssen, Glaxo SmithKline, Pfizer, Kowa, and the Cystic Fibrosis  
692 Foundation. L.S.P. is a cofounder, officer, board member, and stockholder of a diabetes management-  
693 related software company names Diasyst, Inc. S.L.D. has received research grant support from the  
694 following for-profit companies through the University of Utah or the Western Institute for Biomedical  
695 Research (VA Salt Lake City's affiliated non-profit): AbbVie Inc., Anolinx LLC, Astellas Pharma Inc.,  
696 AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli  
697 Lilly and Company, Genentech Inc., Genomic Health, Inc., Gilead Sciences Inc., GlaxoSmithKline PLC,  
698 Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic  
699 Laboratories, Inc., Novartis International AG, and PAREXEL International Corporation.

700

#### 701 **Ethics statement**

702 The Central Veterans Affairs Institutional Review Board (IRB) and site-specific Research and  
703 Development Committees approved the Million Veteran Program study. The Vanderbilt University  
704 Medical Center IRB approved the use of BioVU data for this study. All other cohorts participating in this  
705 meta-analysis have ethical approval from their local institutions. All relevant ethical regulations were  
706 followed.

707

#### 708 **Consortia**

709 VA Million Veteran Program

710 Regeneron Genetics Center

711 The HPAP Consortium



712 **Contributions**

713 M.V., J.M.K., K.-M.C., D.S., B.F.V., P.S.T., C.J.O. were responsible for the concept and design. The  
714 acquisition, analysis or interpretation of data were performed by M.V., J.M.K., K.-M.C., D.S., B.F.V.,  
715 P.S.T., R.L.J., C.T., T.L.A., J.E.H., J.Z., J.H., K.M.L, D.K., S.P., J.D., O.M., A.R., N.Q., S.S.S., S.H., I.H.Q, M.N.A,  
716 U.J., A.J., S.A., X.S., L.G., K.K., K.S., Y.V.S., S.L.D., K.C., J.S.L., J.M.G., L.S.P., D.R.M., J.B.M., P.R., P.W.W.,  
717 T.L.E., D.J.R., S.M.D., and C.J.O. The authors M.V. and D.S. drafted the manuscript. The critical revision of  
718 the manuscript for important intellectual content was carried out by M.V., J.M.K., K.-M.C., D.S., B.F.V.,  
719 P.S.T., C.T., J.Z., J.H., D.K., X.S., L.G., K.K., K.S., L.S.P., J.B.M., P.R., T.L.E., S.M.D., and C.J.O. Finally, K.-M.C.,  
720 D.S., and B.F.V. provided administrative, technical, or material support.

721

722 **Reporting Summary**

723 Further information on research design is available in the Nature Research Reporting Summary linked to  
724 this article.

725

726 **Data availability**

727 The full summary level association data from the trans-ancestry, European, African American, Hispanic,  
728 and Asian meta-analysis from this report will be available through dbGAP (Accession codes will be  
729 available before publication).

730

731

732

733 **Code availability**

734 Imputation was performed using MiniMac4 and EAGLE, association analysis was performed using  
735 PLINK2A and XWAS. Post-GWAS processing software include: FlashPCA, KING, METAL, GCTA-COJO, S-  
736 PrediXcan, SUGEN, DEPICT, SIDER, and DGidb as outlined in the Online Methods. Clear code for analysis  
737 is available at their associated websites. Additional analyses were performed in R-3.2.

738

## 739 References

- 740 1. IDF Diabetes Atlas, 8th edn. *International Diabetes Federation* (2017).  
741 2. Standards of Medical Care in Diabetes, 2018. *Diabetes Care* **41**, S1-S2 (2018).  
742 3. Gaziano, J.M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences on health  
743 and disease. *J Clin Epidemiol* **70**, 214-23 (2016).  
744 4. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using high-density  
745 imputation and islet-specific epigenome maps. *Nat Genet* **50**, 1505-1513 (2018).  
746 5. Levin, M.G. *et al.* Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac  
747 Catheterization. *Circ Genom Precis Med* **11**, e002352 (2018).  
748 6. Saleheen, D. *et al.* Human knockouts and phenotypic analysis in a cohort with a high rate of  
749 consanguinity. *Nature* **544**, 235-239 (2017).  
750 7. Suzuki, K. *et al.* Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese  
751 population. *Nat Genet* **51**, 379-386 (2019).  
752 8. Berglund, G., Elmstahl, S., Janzon, L. & Larsson, S.A. The Malmo Diet and Cancer Study. Design and  
753 feasibility. *J Intern Med* **233**, 45-51 (1993).  
754 9. Reilly, M.P. *et al.* Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and  
755 association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two  
756 genome-wide association studies. *Lancet* **377**, 383-92 (2011).  
757 10. Bonas-Guarch, S. *et al.* Re-analysis of public genetic data reveals a rare X-chromosomal variant  
758 associated with type 2 diabetes. *Nat Commun* **9**, 321 (2018).  
759 11. Xue, A. *et al.* Genome-wide association analyses identify 143 risk variants and putative regulatory  
760 mechanisms for type 2 diabetes. *Nat Commun* **9**, 2941 (2018).  
761 12. Flannick, J. *et al.* Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. *Nat Genet*  
762 **46**, 357-63 (2014).  
763 13. Flannick, J. *et al.* Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. *Nature*  
764 **570**, 71-76 (2019).  
765 14. Klarin, D. *et al.* Genome-wide association study of peripheral artery disease in the Million Veteran  
766 Program. *Nat Med* **25**, 1274-1279 (2019).  
767 15. Barbeira, A.N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression  
768 variation inferred from GWAS summary statistics. *Nat Commun* **9**, 1825 (2018).  
769 16. Kuhn, M., Letunic, I., Jensen, L.J. & Bork, P. The SIDER database of drugs and side effects. *Nucleic*  
770 *Acids Res* **44**, D1075-9 (2016).  
771 17. Cotto, K.C. *et al.* DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. *Nucleic*  
772 *Acids Res* **46**, D1068-D1073 (2018).  
773 18. Ng, M.C. *et al.* Meta-analysis of genome-wide association studies in African Americans provides  
774 insights into the genetic architecture of type 2 diabetes. *PLoS Genet* **10**, e1004517 (2014).  
775 19. Chen, J. *et al.* Genome-wide association study of type 2 diabetes in Africa. *Diabetologia* **62**, 1204-  
776 1211 (2019).  
777 20. Palmer, N.D. *et al.* A genome-wide association search for type 2 diabetes genes in African Americans.  
778 *PLoS One* **7**, e29202 (2012).  
779 21. Kleiner, S. *et al.* Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased  
780 insulin secretory capacity. *Proc Natl Acad Sci U S A* **115**, E7642-E7649 (2018).  
781 22. Mahajan, A. *et al.* Refining the accuracy of validated target identification through coding variant fine-  
782 mapping in type 2 diabetes. *Nat Genet* **50**, 559-571 (2018).  
783 23. Carrano, A.C., Mulas, F., Zeng, C. & Sander, M. Interrogating islets in health and disease with single-  
784 cell technologies. *Mol Metab* **6**, 991-1001 (2017).


- 785 24. Martin, C.K., Han, H., Anton, S.D., Greenway, F.L. & Smith, S.R. Effect of valproic acid on body weight,  
786 food intake, physical activity and hormones: results of a randomized controlled trial. *J*  
787 *Psychopharmacol* **23**, 814-25 (2009).
- 788 25. Perry, J.R. & Frayling, T.M. New gene variants alter type 2 diabetes risk predominantly through  
789 reduced beta-cell function. *Curr Opin Clin Nutr Metab Care* **11**, 371-7 (2008).
- 790 26. Buse, M. *et al.* Expanding the phenotype of reciprocal 1q21.1 deletions and duplications: a case  
791 series. *Ital J Pediatr* **43**, 61 (2017).
- 792 27. Devi, R.R. & Vijayalakshmi, P. Novel mutations in GJA8 associated with autosomal dominant  
793 congenital cataract and microcornea. *Mol Vis* **12**, 190-5 (2006).
- 794 28. Mackay, D.S., Bennett, T.M., Culican, S.M. & Shiels, A. Exome sequencing identifies novel and  
795 recurrent mutations in GJA8 and CRYGD associated with inherited cataract. *Hum Genomics* **8**, 19  
796 (2014).
- 797 29. Luo, J. *et al.* TCF7L2 variation and proliferative diabetic retinopathy. *Diabetes* **62**, 2613-7 (2013).
- 798 30. Young, T.L. *et al.* Whole genome expression profiling of normal human fetal and adult ocular tissues.  
799 *Exp Eye Res* **116**, 265-78 (2013).
- 800 31. Eiden, L.E., Schafer, M.K., Weihe, E. & Schutz, B. The vesicular amine transporter family (SLC18):  
801 amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of  
802 monoamines and acetylcholine. *Pflugers Arch* **447**, 636-40 (2004).
- 803 32. Sharma, P. & Sharma, R. Toxic optic neuropathy. *Indian J Ophthalmol* **59**, 137-41 (2011).
- 804 33. Tokonami, N. *et al.* Uromodulin is expressed in the distal convoluted tubule, where it is critical for  
805 regulation of the sodium chloride cotransporter NCC. *Kidney Int* **94**, 701-715 (2018).
- 806 34. Pattaro, C. *et al.* Genetic associations at 53 loci highlight cell types and biological pathways relevant  
807 for kidney function. *Nat Commun* **7**, 10023 (2016).
- 808 35. Canela-Xandri, O., Rawlik, K. & Tenesa, A. An atlas of genetic associations in UK Biobank. *Nat Genet*  
809 **50**, 1593-1599 (2018).
- 810 36. Guo, H.F. & Vander Kooi, C.W. Neuropilin Functions as an Essential Cell Surface Receptor. *J Biol Chem*  
811 **290**, 29120-6 (2015).
- 812 37. Lieb, W. *et al.* Genome-wide meta-analyses of plasma renin activity and concentration reveal  
813 association with the kininogen 1 and prekallikrein genes. *Circ Cardiovasc Genet* **8**, 131-40 (2015).
- 814 38. Li, J., Matye, D.J. & Li, T. Insulin resistance induces posttranslational hepatic sortilin 1 degradation in  
815 mice. *J Biol Chem* **290**, 11526-36 (2015).
- 816 39. Ehret, G.B. *et al.* The genetics of blood pressure regulation and its target organs from association  
817 studies in 342,415 individuals. *Nat Genet* **48**, 1171-1184 (2016).
- 818 40. Sung, Y.J. *et al.* A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior  
819 Identifies Multiple Significant Loci for Blood Pressure. *Am J Hum Genet* **102**, 375-400 (2018).
- 820 41. Maass, P.G. *et al.* PDE3A mutations cause autosomal dominant hypertension with brachydactyly. *Nat*  
821 *Genet* **47**, 647-53 (2015).
- 822 42. Landa, L.R., Jr. *et al.* Interplay of Ca<sup>2+</sup> and cAMP signaling in the insulin-secreting MIN6 beta-cell line.  
823 *J Biol Chem* **280**, 31294-302 (2005).
- 824 43. Shin, S. *et al.* CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult  
825 mouse beta-cells. *Mol Metab* **3**, 803-12 (2014).
- 826 44. Omar, B., Banke, E., Ekelund, M., Frederiksen, S. & Degerman, E. Alterations in cyclic nucleotide  
827 phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity. *Nutr*  
828 *Diabetes* **1**, e13 (2011).
- 829 45. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.  
830 *Bioinformatics* **26**, 2867-73 (2010).
- 831 46. Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74 (2015).
- 832 47. Loh, P.R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat Genet*  
833 **48**, 1443-1448 (2016).

- 834 48. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284-1287  
835 (2016).
- 836 49. Abraham, G. & Inouye, M. Fast principal component analysis of large-scale genome-wide data. *PLoS*  
837 *One* **9**, e93766 (2014).
- 838 50. Fang, H. *et al.* Harmonizing genetic ancestry and self-identified race/ethnicity in genome-wide  
839 association studies. *Am J Hum Gen* **105**, 763-772 (2019).
- 840 51. Tirschwell, D.L. & Longstreth, W.T., Jr. Validating administrative data in stroke research. *Stroke* **33**,  
841 2465-70 (2002).
- 842 52. Levey, A.S. *et al.* Definition and classification of chronic kidney disease: a position statement from  
843 Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* **67**, 2089-100 (2005).
- 844 53. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.  
845 *Gigascience* **4**, 7 (2015).
- 846 54. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* **48**,  
847 1279-83 (2016).
- 848 55. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association  
849 scans. *Bioinformatics* **26**, 2190-1 (2010).
- 850 56. Gao, F. *et al.* XWAS: A Software Toolset for Genetic Data Analysis and Association Studies of the X  
851 Chromosome. *J Hered* **106**, 666-71 (2015).
- 852 57. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait  
853 analysis. *Am J Hum Genet* **88**, 76-82 (2011).
- 854 58. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122 (2016).
- 855 59. Consortium, G.T. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-5 (2013).
- 856 60. Ko, Y.A. *et al.* Genetic-Variation-Driven Gene-Expression Changes Highlight Genes with Important  
857 Functions for Kidney Disease. *Am J Hum Genet* **100**, 940-953 (2017).
- 858 61. Ackermann, A.M., Wang, Z., Schug, J., Najj, A. & Kaestner, K.H. Integration of ATAC-seq and RNA-seq  
859 identifies human alpha cell and beta cell signature genes. *Mol Metab* **5**, 233-244 (2016).
- 860 62. Gamazon, E.R. *et al.* A gene-based association method for mapping traits using reference  
861 transcriptome data. *Nat Genet* **47**, 1091-8 (2015).
- 862 63. Hormozdiari, F. *et al.* Colocalization of GWAS and eQTL Signals Detects Target Genes. *Am J Hum*  
863 *Genet* **99**, 1245-1260 (2016).
- 864 64. Verma, A. & Ritchie, M.D. Current Scope and Challenges in Phenome-Wide Association Studies. *Curr*  
865 *Epidemiol Rep* **4**, 321-329 (2017).
- 866 65. Denny, J.C. *et al.* PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-  
867 disease associations. *Bioinformatics* **26**, 1205-10 (2010).
- 868 66. Carroll, R.J., Bastarache, L. & Denny, J.C. R PheWAS: data analysis and plotting tools for phenome-  
869 wide association studies in the R environment. *Bioinformatics* **30**, 2375-6 (2014).
- 870 67. Lin, D.Y. *et al.* Genetic association analysis under complex survey sampling: the Hispanic Community  
871 Health Study/Study of Latinos. *Am J Hum Genet* **95**, 675-88 (2014).
- 872 68. Richardson, D.B. & Kaufman, J.S. Estimation of the relative excess risk due to interaction and  
873 associated confidence bounds. *Am J Epidemiol* **169**, 756-60 (2009).
- 874 69. Choi, S.W. & O'Reilly, P.F. PRSice-2: Polygenic Risk Score software for biobank-scale data. *Gigascience*  
875 **8**(2019).
- 876 70. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat Genet*  
877 **47**, 1236-41 (2015).
- 878 71. Pers, T.H. *et al.* Biological interpretation of genome-wide association studies using predicted gene  
879 functions. *Nat Commun* **6**, 5890 (2015).

880

881

882 **Figure 1:** Trans-ancestry GWAS meta-analysis identifies 318 loci associated with T2D.




883  
884 The graph represents a circos plot. The outer track corresponds to  $-\log_{10}(P)$  for association with T2D in  
885 the trans-ethnic meta-analysis (y axis truncated at 30), by chromosomal position. The red line indicates  
886 genome-wide significance ( $P=5.0 \times 10^{-8}$ ). Purple gene labels indicated genes identified in skeletal  
887 muscle eQTLs by S-PrediXcan analysis, red-labeled gene names in adipose eQTLs, black-labeled gene

888 names in pancreas eQTLs, and blue-labeled gene names were identified in eQTLs from arteries. The  
889 green band corresponds to measures of heterogeneity related to the index SNPs associated with T2D.  
890 Dot sizes are proportional to I<sup>2</sup> or ancestry-related heterogeneity. The inner track corresponds to –  
891 log<sub>10</sub>(P) for association with skeletal muscle, adipose, pancreas, and artery tissue eQTLs from S-  
892 PrediXcan analysis (y axis truncated at 20), by chromosomal position. The red line indicates genome-  
893 wide significance (P=5.0×10<sup>-08</sup>). Inset, effects of all 318 index SNPs on T2D by minor allele frequency,  
894 stratified and colored by ancestral group.

895

896 **Figure 2: T2D gPRS is mainly predictive of micro vascular outcomes.**



897

898 A T2D gPRS was calculated and categorized into deciles based on the scores in controls. The PRS-

899 outcome associations are shown for macrovascular outcomes (CHD, CKD and PAD) and for microvascular

900 outcomes (retinopathy, neuropathy, and acute ischemic stroke). Effect sizes and 95% confidence

901 intervals are shown per decile per micro- or macrovascular outcome. For each of the complication

902 outcomes separate logistic regression model are fitted for people with T2D, and the models include the

903 following independent variables: T2D PRS (from Diamante consortium), age, gender, BMI, and 10 PCA's.

904 For coronary heart disease, a CHD PRS (from CardiogramplusC4DplusUKBB) is included in the regression

905 model as an additional covariate. For acute ischemic stroke, a stroke PRS (from Megastroke consortium)

906 is included in the regression model as an additional covariate. For chronic kidney disease, a CKD PRS

907 (from CKDgen consortium) is included in the regression model as an additional covariate.



**Table 1:** T2D locus discovery in African Americans

Description	leadSNP	rsid	EA	NEA	EAF	Beta	SE	P	N	Ncojo	literatureSNP
Novel AA	chr12:38710523	rs7315028	G	A	0.882	0.124	0.022	1.5E-08	56150	1	-
	chr12:57968738	rs11172254	G	A	0.817	0.097	0.017	1.8E-08	56150	1	-
	chr12:88338461	rs10745460	T	A	0.660	0.079	0.014	3.7E-08	56150	0	-
Novel TE	chr7:50887174	rs7781440	C	T	0.284	-0.086	0.015	5.3E-09	56150	0	-
	chr12:80985872	rs1528287	G	T	0.059	-0.494	0.080	8.2E-10	56150	1	-
Established	chr3:123065778	rs11708067	G	A	0.151	-0.118	0.018	2.3E-11	56150	0	chr3:123082398
	chr3:185534482	rs9859406	G	A	0.257	-0.115	0.015	5.7E-14	56150	0	chr3:185829891
	chr5:55807370	rs464605	C	T	0.429	-0.077	0.013	1.1E-09	56150	0	chr5:55860781
	chr6:39016636	rs10305420	C	T	0.920	0.142	0.025	8.5E-09	56150	0	chr6:39282371
	chr7:15064896	-	G	T	0.565	0.101	0.013	2.7E-15	56150	0	chr7:15060429
	chr7:28180556	rs864745	C	T	0.257	-0.083	0.014	1.1E-08	56150	0	chr7:28198677
	chr7:44185088	rs2908274	G	A	0.359	-0.089	0.014	5.4E-11	56150	1	chr7:44266184
	chr8:41510260	rs12550613	G	C	0.310	-0.114	0.014	5.5E-16	56150	0	chr8:41537318
	chr8:118166327	rs60461843	T	A	0.939	0.172	0.028	1.3E-09	56150	1	chr8:118024315
	chr9:139241595	rs28562046	G	C	0.709	0.080	0.014	2.8E-08	56150	0	chr9:139737088
	chr10:114758349	rs7903146	C	T	0.706	-0.226	0.014	5.6E-60	56150	0	chr10:114871594
	chr11:2691500	rs231361	G	A	0.656	-0.080	0.013	2.2E-09	56150	2	chr11:2717680
	chr11:2858546	rs2237897	C	T	0.908	0.143	0.024	2.2E-09	56150	1	chr11:2717680
	chr12:66215214	rs2583938	T	A	0.197	-0.123	0.018	3.3E-12	56150	0	chr12:66358347
	chr15:77776498	rs952471	G	C	0.534	0.077	0.013	4.2E-09	56150	0	chr15:77339496
	chr16:53811788	rs62033400	G	A	0.102	0.151	0.021	6.1E-13	56150	1	chr16:53758720

**Table 2a:** T2D chromosome X analysis (overall results)

Population	leadSNP	EA	NEA	EAF	Novel	literatureSNP	nearestGene	allCases	allControls	allBeta	allSE	allP
Transethnic	chrX:19497290	A	G	0.968	1	-	MAP3K15	102683	170726	0.131	0.023	1.4E-08
	chrX:20009166	T	C	0.323	1	-	CXorf23;MAP7D2	102683	170726	0.058	0.010	7.9E-09
	chrX:31851610	T	C	0.343	1	-	DMD	102683	170726	0.047	0.009	3.5E-08
	chrX:56902211	A	T	0.612	0	X:57170781	SPIN2A;FAAH2	102683	170726	-0.069	0.010	1.9E-12
	chrX:66168667	A	G	0.277	1	-	AR;EDA2R	102683	170726	0.082	0.011	1.9E-13
	chrX:109888390	A	C	0.364	1	-	RGAG1;CHRDL1	102683	170726	-0.048	0.008	7.7E-09
	chrX:117955250	T	C	0.231	0	X:117915163	IL13RA1	102683	170726	0.077	0.010	4.1E-15
	chrX:124390172	T	C	0.853	1	-	TENM1	102683	170726	-0.075	0.013	9.0E-09
	chrX:135859359	C	G	0.407	1	-	ARHGEF6	102683	170726	-0.049	0.008	7.3E-09
	chrX:153882606	C	G	0.026	0	X:152908887	FAM58A;DUSP9	102683	170726	-0.486	0.026	3.0E-78
European	chrX:56759371	T	G	0.218	0	X:57170781	SPIN2A;FAAH2	69869	127197	0.069	0.013	1.7E-08
	chrX:66316809	G	A	0.290	1	-	EDA2R	69869	127197	0.077	0.013	3.4E-09
	chrX:117877437	A	G	0.223	0	X:117915163	IL13RA1	69869	127197	0.118	0.013	5.5E-20
	chrX:152898928	C	A	0.247	0	X:152908887	FAM58A;DUSP9	69869	127197	-0.163	0.012	7.9E-46
African	chrX:67255974	C	T	0.189	1	-	AR;OPHN1	23305	30140	0.104	0.019	3.4E-08
American	chrX:132597984	C	T	0.282	1	-	GPC3;GPC4	23305	30140	0.135	0.024	1.4E-08
	chrX:153882606	C	G	0.026	0	X:152908887	FAM58A;DUSP9	23305	30140	-0.500	0.027	1.6E-76

**Table 2b:** T2D chromosome X analysis (stratified results by gender)

Population	leadSNP	EA	EAF	mCase	mCntrls	mBeta	mSE	mP	fCase	fCntrls	fBeta	fSE	fP	hetP
Transethnic	chrX:19497290	A	0.968	97456	153021	0.128	0.025	5.1E-07	5227	17705	0.147	0.056	8.0E-03	0.751
	chrX:20009166	T	0.323	97456	153021	0.065	0.011	5.8E-10	5227	17705	-0.005	0.030	8.7E-01	0.029
	chrX:31851610	T	0.343	97456	153021	0.051	0.009	1.3E-08	5227	17705	0.011	0.025	6.7E-01	0.130
	chrX:56902211	A	0.612	97456	153021	-0.074	0.010	1.0E-12	5227	17705	-0.028	0.031	3.6E-01	0.156
	chrX:66168667	A	0.277	97456	153021	0.080	0.012	1.4E-11	5227	17705	0.094	0.033	4.3E-03	0.696
	chrX:109888390	A	0.364	97456	153021	-0.044	0.009	4.2E-07	5227	17705	-0.075	0.025	2.3E-03	0.240
	chrX:117955250	T	0.231	97456	153021	0.082	0.010	2.4E-15	5227	17705	0.034	0.029	2.5E-01	0.118
	chrX:124390172	T	0.853	97456	153021	-0.075	0.014	1.1E-07	5227	17705	-0.075	0.034	2.7E-02	1.000
	chrX:135859359	C	0.407	97456	153021	-0.052	0.009	4.8E-09	5227	17705	-0.021	0.026	4.3E-01	0.250
	chrX:153882606	C	0.026	97456	153021	-0.517	0.029	1.7E-72	5227	17705	-0.349	0.061	1.1E-08	0.013
European	chrX:56759371	T	0.218	67020	115901	0.076	0.012	1.1E-09	2849	11296	-0.014	0.039	7.3E-01	0.035
	chrX:66316809	G	0.290	67020	115901	0.073	0.014	1.1E-07	2849	11296	0.134	0.042	1.4E-03	0.126
	chrX:117877437	A	0.223	67020	115901	0.118	0.000	3.6E-19	2849	11296	0.121	0.041	3.1E-03	0.943
	chrX:152898928	C	0.247	67020	115901	-0.166	0.000	1.6E-44	2849	11296	-0.131	0.037	4.6E-04	0.377
African	chrX:67255974	C	0.189	21316	25287	0.117	0.020	2.6E-09	1989	4853	0.021	0.041	6.1E-01	0.030
American	chrX:132597984	C	0.282	21316	25287	0.121	0.027	7.1E-06	1989	4853	0.231	0.059	8.9E-05	0.080
	chrX:153882606	C	0.026	21316	25287	-0.519	0.029	2.2E-70	1989	4853	-0.366	0.062	4.1E-09	0.025

**Table 3a:** Genome-wide interaction analysis of vascular and non-vascular complications (overall results)

Type	Outcome	SNP	RSID	REF	ALT	ALT_AF	P-interaction	Gene
Vascular	CHD	<b>9:22076071</b>	<b>rs1831733</b>	T	C	<b>0.482</b>	<b>1.6E-13</b>	<b>CDKN2B;CDKN2A</b>
		<b>1:109821511</b>	<b>rs602633</b>	G	T	<b>0.216</b>	<b>4.4E-10</b>	<b>SORT1</b>
		12:20231526	rs71039916	TCTTA	T	0.034	8.2E-09	PDE3A
	AIS	1:15429233	rs491203	G	A	0.057	7.6E-09	TMEM51
		8:94056373	rs2134937	T	C	0.049	3.3E-08	TRIQQ
	PAD	8:97331026	rs3104154	C	T	0.044	3.0E-08	PTDSS1
Non-Vascular	Retinopathy	1:146606059	rs76754787	ATT	AT	0.030	1.2E-11	GJA8
		10:30992882	rs10733997	A	G	0.037	9.7E-09	SVILP2
		10:119646217	rs2255624	T	G	0.032	1.6E-08	SLC18A2
		10:114767771	rs4132670	G	A	0.319	2.1E-08	TCF7L2
	CKD	<b>16:20356012</b>	<b>rs34857077</b>	<b>G</b>	<b>GA</b>	<b>0.237</b>	<b>6.4E-19</b>	<b>UMOD</b>
		4:181816870	rs2177223	T	C	0.038	2.8E-08	TENM3
	Neuropathy	2:206668118	rs78977169	CATA	C	0.023	3.4E-08	NRP2

CHD, coronary heart disease; AIS, acute ischemic stroke; PAD, peripheral artery disease; CKD, chronic kidney disease

**Table 3b:** Genome-wide interaction analysis of vascular and non-vascular complications (T2D strata specific effect estimates)

Type	Outcome	rsid	T2D					No T2D				
			Cases	Controls	Beta	SE	P	Cases	Controls	Beta	SE	P
Vascular	CHD	<b>rs1831733</b>	<b>30311</b>	<b>39568</b>	<b>0.123</b>	<b>0.011</b>	<b>2.6E-29</b>	<b>25974</b>	<b>101377</b>	<b>0.152</b>	<b>0.010</b>	<b>3.9E-52</b>
		<b>rs602633</b>	<b>30311</b>	<b>39568</b>	<b>-0.124</b>	<b>0.014</b>	<b>4.2E-19</b>	<b>25974</b>	<b>101377</b>	<b>-0.108</b>	<b>0.013</b>	<b>9.9E-17</b>
		rs71039916	30311	39568	-0.116	0.031	9.1E-05	25974	101377	-0.002	0.029	0.945
	AIS	rs491203	5981	61240	-0.161	0.044	1.3E-04	5815	117241	0.060	0.040	0.134
		rs2134937	5981	61240	-0.153	0.047	5.7E-04	5815	117241	0.107	0.043	0.013
	PAD	rs3104154	20223	49656	-0.104	0.029	1.7E-04	15659	111692	0.044	0.029	0.129
Non-Vascular	Retinopathy	rs76754787	9097	44821	-0.183	0.050	1.3E-04	4784	78717	0.165	0.059	0.005
		rs10733997	9097	44821	-0.156	0.045	2.6E-04	4784	78717	0.069	0.055	0.210
		rs2255624	9097	44821	-0.160	0.048	4.3E-04	4784	78717	0.056	0.060	0.351
		rs4132670	9097	44821	0.081	0.017	9.5E-07	4784	78717	-0.061	0.023	0.008
	CKD	<b>rs34857077</b>	<b>34588</b>	<b>35291</b>	<b>-0.149</b>	<b>0.013</b>	<b>1.1E-30</b>	<b>32815</b>	<b>94536</b>	<b>-0.123</b>	<b>0.012</b>	<b>1.2E-24</b>
		rs2177223	34588	35291	-0.117	0.030	4.8E-05	32815	94536	0.048	0.026	0.065
	Neuropathy	rs78977169	22943	37569	-0.152	0.041	1.0E-04	17532	72762	0.041	0.040	0.305

CHD, coronary heart disease; AIS, acute ischemic stroke; PAD, peripheral artery disease; CKD, chronic kidney disease

**Table 4a:** Polygenic risk scores and vascular complications

Type	Outcome	T2D PRS-decile	Cases	Controls	OR (95%CI)	P	P-linear*
Vascular	Coronary Heart Disease <sup>†</sup>	0-10%	2913	3924	1.00 (Ref)	-	0.636
		10-20%	2940	3924	1.01 (0.92-1.12)	0.811	
		20-30%	2958	3924	0.98 (0.89-1.08)	0.742	
		30-40%	2934	3924	0.99 (0.90-1.09)	0.835	
		40-50%	2988	3924	1.01 (0.92-1.11)	0.801	
		50-60%	3001	3924	0.98 (0.90-1.08)	0.744	
		60-70%	2977	3924	1.01 (0.92-1.10)	0.887	
		70-80%	2916	3924	1.02 (0.93-1.12)	0.632	
		80-90%	3032	3924	0.96 (0.88-1.05)	0.391	
	90-100%	3038	3924	1.03 (0.94-1.12)	0.537		
	Acute Ischemic Stroke <sup>‡</sup>	0-10%	555	6027	1.00 (Ref)	-	0.070
		10-20%	563	6027	0.90 (0.76-1.07)	0.238	
		20-30%	583	6027	0.98 (0.83-1.15)	0.782	
		30-40%	619	6027	0.98 (0.84-1.15)	0.821	
		40-50%	530	6027	0.99 (0.85-1.16)	0.924	
		50-60%	576	6027	0.99 (0.85-1.16)	0.941	
		60-70%	645	6027	0.97 (0.83-1.13)	0.672	
		70-80%	590	6027	1.04 (0.90-1.20)	0.611	
		80-90%	558	6027	1.05 (0.91-1.22)	0.494	
	90-100%	627	6027	1.02 (0.89-1.17)	0.784		
	Peripheral Artery Disease	0-10%	1966	4871	1.00 (Ref)	-	2.0E-07
		10-20%	1964	4871	1.00 (0.93-1.08)	0.927	
		20-30%	1948	4871	1.01 (0.93-1.08)	0.890	
		30-40%	1984	4871	1.04 (0.96-1.12)	0.361	
		40-50%	1964	4871	1.03 (0.96-1.11)	0.425	
		50-60%	1950	4871	1.02 (0.95-1.10)	0.559	
		60-70%	1972	4871	1.05 (0.98-1.14)	0.165	
70-80%		1960	4871	1.05 (0.97-1.13)	0.203		
80-90%		2019	4871	1.10 (1.02-1.19)	0.010		
90-100%	2102	4871	1.2 (1.11-1.29)	1.9E-06			

**Table 4b:** Polygenic risk scores and non-vascular complications

Type	Outcome	T2D PRS-decile	Cases	Controls	OR (95%CI)	P	P-linear*
Non-Vascular	Retinopathy	0-10%	792	4533	1.00 (Ref)	-	3.1E-32
		10-20%	832	4533	1.08 (0.97-1.20)	0.158	
		20-30%	795	4533	1.05 (0.94-1.17)	0.364	
		30-40%	852	4533	1.14 (1.02-1.26)	0.019	
		40-50%	814	4533	1.08 (0.97-1.20)	0.152	
		50-60%	891	4533	1.20 (1.08-1.33)	6.8E-04	
		60-70%	901	4533	1.25 (1.13-1.39)	3.1E-05	
		70-80%	936	4533	1.30 (1.17-1.45)	6.8E-07	
		80-90%	1031	4533	1.47 (1.33-1.63)	2.2E-13	
	90-100%	1069	4533	1.59 (1.44-1.77)	4.2E-19		
	Chronic Kidney Disease <sup>5</sup>	0-10%	3446	3391	1.00 (Ref)	-	7.3E-06
		10-20%	3490	3391	1.03 (0.93-1.15)	0.508	
		20-30%	3439	3391	1.04 (0.94-1.14)	0.488	
		30-40%	3463	3391	1.05 (0.95-1.16)	0.323	
		40-50%	3370	3391	1.04 (0.95-1.14)	0.409	
		50-60%	3362	3391	1.07 (0.97-1.17)	0.166	
		60-70%	3389	3391	1.07 (0.98-1.17)	0.129	
		70-80%	3285	3391	1.07 (0.98-1.17)	0.121	
		80-90%	3373	3391	1.07 (0.98-1.16)	0.151	
	90-100%	3326	3391	1.16 (1.07-1.26)	5.9E-04		
	Neuropathy	0-10%	2176	3814	1.00 (Ref)	-	7.9E-08
		10-20%	2193	3814	1.03 (0.96-1.11)	0.436	
		20-30%	2217	3814	1.07 (0.99-1.15)	0.075	
		30-40%	2218	3814	1.06 (0.99-1.15)	0.110	
		40-50%	2217	3814	1.05 (0.98-1.13)	0.192	
		50-60%	2293	3814	1.11 (1.03-1.20)	0.006	
		60-70%	2261	3814	1.10 (1.02-1.18)	0.014	
		70-80%	2253	3814	1.10 (1.02-1.19)	0.009	
		80-90%	2265	3814	1.11 (1.03-1.19)	0.007	
	90-100%	2377	3814	1.21 (1.12-1.30)	9.7E-07		

**Table 5:** Phewas of 2 LoF variants in MVP whites

Gene	rsid	AA.change	phewasPhenotype	P	Cases	Controls	OR	lowCI	highCI
ANKDD1B	rs34358	p.Trp480*	Diabetes mellitus	1.04E-06	62930	104442	0.96	0.95	0.98
			Type 2 diabetes	1.36E-06	62531	104442	0.96	0.95	0.98
			Type 2 diabetes with neurological manifestations	1.63E-05	14159	104442	0.94	0.92	0.97
			Disorders of lipid metabolism	5.03E-08	141535	41406	1.05	1.03	1.07
			Hyperlipidemia	4.66E-08	141408	41406	1.05	1.03	1.07
			Hypercholesterolemia	2.33E-06	32008	41406	1.06	1.03	1.08
CCHCR1	rs3130453	p.Trp78*	Diabetes mellitus	4.26E-05	62930	104442	0.97	0.96	0.98
			Type 1 diabetes	3.99E-07	6566	104442	0.91	0.88	0.95
			Type 2 diabetes	3.96E-05	62531	104442	0.97	0.96	0.98
			Epistaxis or throat hemorrhage	1.96E-05	2751	110902	1.12	1.07	1.19
			Celiac disease	2.72E-19	418	124470	0.52	0.45	0.60
			Microscopic hematuria	1.83E-05	4078	147054	1.1	1.05	1.15
			Psoriatic arthropathy	7.82E-10	1077	140876	0.76	0.70	0.83